1. P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01. (23rd June 2022) Authors: Bobin, A.; Manier, S.; De Keizer, J.; Karlin, L.; Perrot, A.; Hulin, C.; Caillot, D.; Mariette, C.; Lenain, P.; Richez, V.; Tiab, M.; Touzeau, C.; Jaccard, A.; Decaux, O.; Araujo, C.; Belhadj, K.; Benboubker, L.; Déal, C.; Macro, M.; Vincent, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 783 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY. (23rd June 2022) Authors: Hulin, C.; Macro, M.; Perrot, A.; Royer, B.; Caillot, D.; Belhadj, K.; Frenzel, L.; Benramdane, R.; Demarquette, H.; Bareau, B.; Darre, S.; Calmettes, C.; Le Calloch, R.; Bouketouche, M.; Laribi, K.; Texier, N.; Willaime, M.; Deal, C.; Moreau, P.; Decaux, O. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 845 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗